EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer

BACKGROUND: Only 40–70% of metastatic colorectal cancers (mCRCs) with wild-type (WT) KRAS oncogene respond to anti-epidermal growth factor receptor (anti-EGFR) antibody treatment. EGFR amplification has been suggested as an additional marker to predict the response. However, improved methods for bri...

Descripción completa

Detalles Bibliográficos
Autores principales: Ålgars, A, Lintunen, M, Carpén, O, Ristamäki, R, Sundström, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142805/
https://www.ncbi.nlm.nih.gov/pubmed/21694725
http://dx.doi.org/10.1038/bjc.2011.223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142805/
https://www.ncbi.nlm.nih.gov/pubmed/21694725
http://dx.doi.org/10.1038/bjc.2011.223

Ejemplares similares